The highest rate of hepatitis C is the omission of legal infectious diseases
The latest release of data show that patients with chronic hepatitis B after stopping access to treatment “clinical cure” (ie, the surface of antigen to be cleared) and the ratio increased year by year.
19, China will usher in the first two “World Hepatitis Day.” Yesterday morning, the Chinese Foundation for Hepatitis Prevention Network, held its first press conference and official launch of “Together, hepatitis popular walking Shenzhou” large-scale science popularization activities. At the same time, the Chinese Foundation for Hepatitis Prevention Joint National Liver Disease prevention and control authority of experts in the field of viral hepatitis co-signed for patients, medical workers and the community’s “2009 World Hepatitis Day Treatment for Hepatitis Control written proposal.”
Reporter learned from the conference, although hepatitis B in China is still a big country, but the clinical cure of chronic hepatitis B is no longer a distant dream. Studies have shown that, through the standard anti-viral treatment of chronic hepatitis B patients with “clinical cure” rate is being increased every year. It is worth noting that the incidence of hepatitis C in China is increasing year by year, in 2008 reported hepatitis C cases are six times more in 2003.
If the suspect got hepatitis, testing should be done as soon as possible.
Chronic Hepatitis B “clinical cure” has gradually increased
Hepatitis B is known as “China’s first disease”, according to the Ministry of Health announced the national population Seroepidemiological survey of hepatitis B, China’s population of hepatitis B surface antigen carrier rate of 7.18%, about 93 million people living with HIV, of which about 1 / 4 will develop chronic liver disease, some patients can develop cirrhosis of the liver, and even the development of liver cancer.
On the majority of patients with chronic hepatitis B is a good news is that the joint efforts of doctors and patients with chronic hepatitis B may be successfully treated. Studies have shown that pegylated interferon treatment of chronic hepatitis B for one year after treatment, it is possible to obtain long-lasting effect. The latest release of data show that patients with chronic hepatitis B after stopping access to treatment “clinical cure” (ie, the surface of antigen to be cleared) and the ratio increased year by year.
Near Liu Cheng hepatitis B patients did not receive antiretroviral therapy
In recent years, through all levels of government and medical personnel, propaganda and education work, the level of public awareness of hepatitis B than in the past already have a substantial increase in the national popularity of the effect of vaccination with hepatitis B vaccine has also been preliminarily showed. Current treatment of hepatitis B, however, are still not optimistic, there are still 59% of chronic hepatitis B patients did not receive anti-viral treatment.
In addition, due to lack of knowledge of hepatitis B treatment, traditional, or that the hepatitis B can not be achieved “clinical cure.” There are also many patients with hepatitis B will “doctor when critically ill” in the standardized treatment of hepatitis B still has many problems: for example, a lot of mixed levels of non-formal medical institutions or individuals, deliberately exaggerated the treatment effect, misleading patients and their families; due to economic so for various reasons, patients receive regular treatment group the proportion of poor performance in drug selection, the use of non-standard, receive regular monitoring and systematic follow-up was even lower. All this makes the missing through the rational treatment of patients with a satisfactory efficacy of the best time to its negative impact on work and life and increased the burden to society.
Experts also pointed out that the treatment of chronic hepatitis B in addition to formal anti-virus treatment, regular monitoring of the key to determining the success or failure of treatment. During treatment through the strengthening of e antigen and surface antigen monitoring, will enable physicians and patients understand the illness, to guide individualized treatment to improve efficacy, increase the probability of success.
The highest rate of hepatitis C omission of legal infectious diseases
In addition to chronic hepatitis B, according to China Center for Disease Control and Prevention data show that infectious diseases reported in recent years, the number of China’s reported incidence of hepatitis C has also increased year by year, in 2003 the number of reported incidence 6 times.
The Nanfang Hospital, Southern Medical University Professor Hou Jinlin, director of Infectious Diseases in an interview a few days ago, also pointed out that omitting the highest rate of hepatitis C is a statutory infectious disease, failed to report rates as high as more than half.
Due to hepatitis C onset hidden, the public’s inadequate understanding of the disease, at present only 1% of the people on the route of transmission of hepatitis C and prevention measures have a correct understanding, many patients adversely affected by the timing of the standard treatment, resulting in disease progression.
It is reported that hepatitis C is caused by the hepatitis C virus infection in liver inflammatory disease that can be sustained liver damage. As the initial symptoms was not obvious, hepatitis C is often easily overlooked, but the diseases are unknowingly continued progress, if not timely diagnosis and treatment, which may develop into cirrhosis and liver cancer.
Hepatitis B virus can be controlled but is difficult to cure difference is that hepatitis C is completely curable, but the key to early detection and early treatment.